Repletion of Ergothioneine in Patients With Kidney Failure

Stanford University

Status: Not yet enrolling

Conditions: Esrd

Treatments: Dietary Supplement: Ergothioneine

Study type: Interventional

Funder types: Other

Identifiers

NCT06487546

75743

Details and patient eligibility

About

Dialysis removes potentially harmful chemicals from the blood but can also remove potentially valuable chemicals. One potentially valuable chemical called ergothioneine, which comes from our diet, is low in the blood of people receiving dialysis. For this research study, we hope to learn how well a daily ergothioneine supplement will replenish the levels in the blood of people with kidney failure.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• kidney failure receiving hemodialysis or peritoneal dialysis

Exclusion criteria

• blood transfusion within 90 days
• taking supplements which contain ergothioneine

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Ergothioneine

Experimental group

Description:

Ergothioneine (range 5 mg to 25 mg) oral daily for up to 16 weeks

Treatment:

Dietary Supplement: Ergothioneine